MOHELNIKOVA-DUCHONOVA, Beatrice, Ondrej STROUHAL, David J. HUGHES, Ivana HOLCATOVA, Martin OLIVERIUS, Zdeněk KALA, Daniele CAMPA, Cosmeri RIZZATO, Federico CANZIAN, Raffaele PEZZILLI, Renata TALAR-WOJNAROWSKA, Ewa MALECKA-PANAS, Cosimo SPERTI, Carlo Federico ZAMBON, Serdio PEDRAZZOLI, Paola FOGAR, Anna Caterina MILANETTO, Gabriele CAPURSO, Giafranco Delle FAVE, Roberto VALENTE, Maria GAZOULI, Giuseppe MALLEO, Rita Teresa LAWLOR, Oliver STROBEL, Thilo HACKERT, Nathalia GIESE, Pavel VODICKA, Ludmila VODICKOVA, Stefano LANDI, Francesca TAVANO, Domenica GIOFFREDA, Ada PIEPOLI, Valerio PAZIENZA, Andrea MAMBRINI, Mariangela PEDATA, Maurizio CANTORE, Franco BAMBI, Stefano ERMINI, Niccola FUNEL, Radmila LEMSTROVA and Pavel SOUCEK. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Scientific Reports. London: Nature Publishing Group, 2017, vol. 7, No 43812, p. 1-11. ISSN 2045-2322. Available from: https://dx.doi.org/10.1038/srep43812.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival
Authors MOHELNIKOVA-DUCHONOVA, Beatrice (203 Czech Republic), Ondrej STROUHAL (203 Czech Republic), David J. HUGHES (372 Ireland), Ivana HOLCATOVA (203 Czech Republic), Martin OLIVERIUS (203 Czech Republic), Zdeněk KALA (203 Czech Republic, guarantor, belonging to the institution), Daniele CAMPA (276 Germany), Cosmeri RIZZATO (276 Germany), Federico CANZIAN (276 Germany), Raffaele PEZZILLI (380 Italy), Renata TALAR-WOJNAROWSKA (616 Poland), Ewa MALECKA-PANAS (616 Poland), Cosimo SPERTI (380 Italy), Carlo Federico ZAMBON (380 Italy), Serdio PEDRAZZOLI (380 Italy), Paola FOGAR (380 Italy), Anna Caterina MILANETTO (380 Italy), Gabriele CAPURSO (380 Italy), Giafranco Delle FAVE (380 Italy), Roberto VALENTE (380 Italy), Maria GAZOULI (300 Greece), Giuseppe MALLEO (380 Italy), Rita Teresa LAWLOR (380 Italy), Oliver STROBEL (276 Germany), Thilo HACKERT (276 Germany), Nathalia GIESE (276 Germany), Pavel VODICKA (203 Czech Republic), Ludmila VODICKOVA (203 Czech Republic), Stefano LANDI (380 Italy), Francesca TAVANO (380 Italy), Domenica GIOFFREDA (380 Italy), Ada PIEPOLI (380 Italy), Valerio PAZIENZA (380 Italy), Andrea MAMBRINI (380 Italy), Mariangela PEDATA (380 Italy), Maurizio CANTORE (380 Italy), Franco BAMBI (380 Italy), Stefano ERMINI (380 Italy), Niccola FUNEL (380 Italy), Radmila LEMSTROVA (203 Czech Republic) and Pavel SOUCEK (203 Czech Republic).
Edition Scientific Reports, London, Nature Publishing Group, 2017, 2045-2322.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 4.122
RIV identification code RIV/00216224:14110/17:00096878
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/srep43812
UT WoS 000395686300001
Keywords in English pancreatic cancer
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 16:06.
Abstract
Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were successfully evaluated in the discovery phase while six significant or suggestive variants entered the validation phase, comprising a total study number of 1,518 cases and 3,908 controls. In the discovery phase, rs2504938, rs9364554, and rs2457571 SNPs were significantly associated with pancreatic cancer risk.
PrintDisplayed: 30/8/2024 00:38